Breast metastasis nine years after nephrectomy for renal cell carcinoma: A case report

Ishigaki, Takayuki; Kinoshita, Satoki; Shimada, Naoki; Miyake, Ryo; Suzuki, Masaaki; Takeyama, Hiroshi

doi:10.1016/j.ijscr.2017.08.008

Cited by 4 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, in approximately 30% of patients, RCC has the propensity to spread to other organs, usually the brain (11%), adrenal glands (15%), liver (41%), bone (42%), lymph nodes (55%), and lungs (70%) [7] , [8] , [9] . Established research studies indicate that metastasis to the breast from extramammary cancer is still less common with primary breast tumors (1%-2% of breast cancers) [10] , [11] , [12] , and RCC metastasis to the breast is rare, occurring only in 3% of all cases [13] , [14] . Traditional cancer therapy, radiation therapy (RT), and chemotherapy are not efficacious in the treatment of advanced breast cancer and RCC [15] .…”

Section: Introductionmentioning

confidence: 99%

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer

Choi

Jeon

Lee

et al. 2019

Translational Oncology

View full text Add to dashboard Cite

Advanced cancer has been shown to be associated with a higher percentage of epigenetic changes than with genetic mutations. Preclinical models have shown that the combination of paclitaxel, sorafenib, and radiation therapy (RT) plays a crucial role in renal cell carcinoma (RCC) and breast cancer. This study aimed to investigate the involvement of mitochondrial cytochrome c–dependent apoptosis in the mechanism of action of a combination of paclitaxel, sorafenib, and RT in RCC and breast cancer. RCC and breast cancer cell lines were exposed to paclitaxel and sorafenib alone or combined in the presence of radiation, and cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay. The synergistic anticancer effects of the combination therapy on cell cycle and intracellular signaling pathways were estimated using flow cytometry and immunoblot analysis. RCC and breast cancer cell line xenograft models were used to examine the antitumor activity in vivo. Our results suggest that paclitaxel, sorafenib, and RT synergistically decreased the viability of RCC and breast cancer cells and significantly induced their apoptosis, as shown by caspase-3 cleavage. Paclitaxel, sorafenib, and radiation cotreatment reduced antiapoptotic factor levels in these cells and, thereby, significantly reduced the tumor volume of RCC and breast cancer cell xenografts. The current study suggests that paclitaxel, sorafenib, and radiation cotreatment was more effective than cotreatment with paclitaxel or sorafenib and radiation. These findings may offer a new therapeutic approach to RCC and breast cancer.

show abstract

Section: Introductionmentioning

confidence: 99%

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer

Choi

Jeon

Lee

et al. 2019

Translational Oncology

View full text Add to dashboard Cite

show abstract

“…In the remaining 22 cases (76%), there was a known history of RCC, all of whom had previously been treated with nephrectomy. The interval between initial diagnosis and finding of breast metastasis ranged between 10 months and 21 years, with a median interval of 5 years [11] .…”

Section: Discussionmentioning

confidence: 99%

Metastatic renal cell carcinoma initially presenting as a unilateral breast lump

Khurram

Amir

Chaudhary

et al. 2021

Radiology Case Reports

View full text Add to dashboard Cite

Breast metastasis from primary renal cell carcinoma is a rare entity and infrequently reported in the literature. We present a case of a 65-year-old lady who presented to breast clinic with a 4-month history of rapidly growing right sided breast lump. She previously had a left mastectomy for breast cancer and a hysterectomy for endometrial cancer. Radiological evaluation with mammography and ultrasound revealed a large heterogeneous right breast lump with prominent vascularity which was biopsied. Histopathological and immunohistochemical features were not supportive of a primary breast carcinoma and favored metastasis from a renal tumor. The patient was unfortunately admitted to hospital due to increasing confusion and neurological symptoms and underwent whole-body cross-sectional CT imaging which demonstrated a giant tumor originating from the right kidney with associated intrathoracic, breast and intracranial metastasis. She was diagnosed with eosinophilic variant metastatic renal cell carcinoma. This case highlights the importance of considering alternative diagnoses to primary breast carcinoma in the context of an initial presentation of a unilateral breast lump.

show abstract

Metastatic Tumors to the Breast

Alvarado‐Cabrero

2018

Practical Atlas of Breast Pathology

View full text Add to dashboard Cite

Breast metastasis nine years after nephrectomy for renal cell carcinoma: A case report

Cited by 4 publications

References 22 publications

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer

Synergistic Activity of Paclitaxel, Sorafenib, and Radiation Therapy in advanced Renal Cell Carcinoma and Breast Cancer

Metastatic renal cell carcinoma initially presenting as a unilateral breast lump

Metastatic Tumors to the Breast

Contact Info

Product

Resources

About